BioRestorative Therapies (BRTX) 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 12, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		4,283,635
Trading Symbol	BRTX
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,016

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current Assets:
Cash	$ 516,190	$ 166,555
Accounts receivable	16,000	93,375
Prepaid expenses and other current assets	14,022	29,348
Total Current Assets	546,212	289,278
Property and equipment, net	602,388	643,087
Intangible assets, net	1,001,293	1,038,741
Security deposit	45,900	45,900
Total Assets	2,195,793	2,017,006
Current Liabilities:
Accounts payable	2,069,680	2,549,042
Accrued expenses and other current liabilities	2,242,294	2,046,795
Accrued interest	65,891	6,823
Current portion of notes payable, net of debt discount of $42,300 and $150,286 at June 30, 2016 and December 31, 2015, respectively	1,320,265	1,009,797
Total Current Liabilities	5,698,130	5,612,457
Accrued interest, non-current portion	3,195	11,011
Notes payable, non-current portion, net of debt discount of $55,659 and $7,999 at June 30, 2016 and December 31, 2015, respectively	499,341	302,001
Total Liabilities	6,200,666	5,925,469
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at June 30, 2016 and December 31, 2015
Common stock, $0.001 par value; Authorized, 30,000,000 shares; Issued 4,179,998 and 3,338,661 shares at June 30, 2016 and December 31, 2015, respectively; Outstanding 4,144,566 and 3,310,729 shares at June 30, 2016 and December 31, 2015, respectively	4,180	3,339
Additional paid-in capital	34,109,071	29,443,704
Accumulated deficit	(38,069,249)	(33,323,506)
Treasury stock, at cost, 35,432 and 27,932 shares at June 30, 2016 and December 31, 2015, respectively	(48,875)	(32,000)
Total Stockholders' Deficiency	(4,004,873)	(3,908,463)
Total Liabilities and Stockholders' Deficiency	$ 2,195,793	$ 2,017,006

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Notes payable current, debt discount	$ 42,300	$ 150,286
Notes payable non-current, debt discount	$ 55,659	$ 7,999
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares Issued	4,179,998	3,338,661
Common stock, shares Outstanding	4,144,566	3,310,729
Treasury stock, at cost shares	35,432	27,932

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenues	$ 16,155	$ 148,764	$ 25,280	$ 333,666
Cost of sales	71	74,645	81	151,077
Gross Profit	16,084	74,119	25,199	182,589
Operating Expenses
Marketing and promotion	18,178	49,091	40,695	94,028
Consulting	550,006	138,991	834,813	504,060
Research and development	608,688	452,488	1,474,732	859,344
General and administrative	982,358	696,353	1,885,239	1,613,927
Total Operating Expenses	2,159,230	1,336,923	4,235,479	3,071,359
Loss From Operations	(2,143,146)	(1,262,804)	(4,210,280)	(2,888,770)
Other Expense
Interest expense	(45,008)	(60,096)	(87,848)	(124,736)
Amortization of debt discount	(65,448)	(71,369)	(402,469)	(140,884)
Loss on extinguishment of notes payable, net	(4,813)	(26,029)	(16,660)	(26,029)
Warrant modification expense			(28,486)
Total Other Expense	(115,269)	(157,494)	(535,463)	(291,649)
Net Loss	$ (2,258,415)	$ (1,420,298)	$ (4,745,743)	$ (3,180,419)
Net Loss Per Share - Basic and Diluted	$ (0.56)	$ (0.64)	$ (1.26)	$ (1.60)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	4,006,617	2,227,400	3,776,207	1,993,544

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
Common Stock [Member]
Balance		$ 3,339
Balance, shares		3,338,661
Shares and warrants issued for cash		$ 558
Shares and warrants issued for cash, shares		558,343
Exercise of warrants for purchase of common stock		$ 61
Exercise of warrants for purchase of common stock, shares		60,831
Conversion of notes payable and accrued interest into common stock		$ 77
Conversion of notes payable and accrued interest into common stock, shares		76,674
Shares issued in satisfaction of accrued services		$ 13
Shares issued in satisfaction of accrued services, shares		13,208
Shares and warrants issued as debt discount in connection with notes payable		$ 6
Shares and warrants issued as debt discount in connection with notes payable, shares		6,000
Shares and warrants issued in exchange of notes payable and accrued interest		$ 103
Shares and warrants issued in exchange of notes payable and accrued interest, shares		102,880
Warrant modifications		$ 0
Beneficial conversion features related to convertible notes payable		0
Stock-based compensation: - common stock		$ 23
Stock-based compensation: - common stock, shares		23,401
Stock-based compensation: - options		$ 0
Stock-based compensation: - options, shares
Return of shares to treasury		$ 0
Return of shares to treasury, shares		0
Net loss		$ 0
Balance	$ 4,180	$ 4,180
Balance, shares	4,179,998	4,179,998
Additional Paid In Capital [Member]
Balance		$ 29,443,704
Shares and warrants issued for cash		2,232,814
Exercise of warrants for purchase of common stock		212,837
Conversion of notes payable and accrued interest into common stock		215,081
Shares issued in satisfaction of accrued services		27,540
Shares and warrants issued as debt discount in connection with notes payable		129,607
Shares and warrants issued in exchange of notes payable and accrued interest		231,377
Warrant modifications		28,486
Beneficial conversion features related to convertible notes payable		215,446
Stock-based compensation: - common stock		53,935
Stock-based compensation: - options		1,318,244
Return of shares to treasury		0
Net loss		0
Balance	$ 34,109,071	34,109,071
Accumulated Deficit [Member]
Balance		(33,323,506)
Shares and warrants issued for cash		0
Exercise of warrants for purchase of common stock		0
Conversion of notes payable and accrued interest into common stock		0
Shares issued in satisfaction of accrued services		0
Shares and warrants issued as debt discount in connection with notes payable		0
Shares and warrants issued in exchange of notes payable and accrued interest		0
Warrant modifications		0
Beneficial conversion features related to convertible notes payable		0
Stock-based compensation: - common stock		0
Stock-based compensation: - options		0
Return of shares to treasury		0
Net loss		(4,745,743)
Balance	(38,069,249)	(38,069,249)
Treasury Stock [Member]
Balance		$ (32,000)
Balance, shares		(27,932)
Shares and warrants issued for cash		$ 0
Exercise of warrants for purchase of common stock		$ 0
Exercise of warrants for purchase of common stock, shares		0
Conversion of notes payable and accrued interest into common stock		$ 0
Conversion of notes payable and accrued interest into common stock, shares		0
Shares issued in satisfaction of accrued services		$ 0
Shares issued in satisfaction of accrued services, shares		0
Shares and warrants issued as debt discount in connection with notes payable		$ 0
Shares and warrants issued in exchange of notes payable and accrued interest		$ 0
Shares and warrants issued in exchange of notes payable and accrued interest, shares		0
Warrant modifications		$ 0
Beneficial conversion features related to convertible notes payable		0
Stock-based compensation: - common stock		0
Stock-based compensation: - options		0
Return of shares to treasury		$ (16,875)
Return of shares to treasury, shares		(7,500)
Net loss		$ 0
Balance	$ (48,875)	$ (48,875)
Balance, shares	(35,432)	(35,432)
Balance		$ (3,908,463)
Shares and warrants issued for cash		2,233,372
Exercise of warrants for purchase of common stock		212,898
Conversion of notes payable and accrued interest into common stock		215,158
Shares issued in satisfaction of accrued services		27,553
Shares and warrants issued as debt discount in connection with notes payable		129,613
Shares and warrants issued in exchange of notes payable and accrued interest		231,480
Warrant modifications		28,486
Beneficial conversion features related to convertible notes payable	$ 0	215,446
Stock-based compensation: - common stock		53,958
Stock-based compensation: - options		$ 1,318,244
Stock-based compensation: - options, shares
Return of shares to treasury		$ (16,875)
Net loss	(2,258,415)	(4,745,743)
Balance	$ (4,004,873)	$ (4,004,873)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash Flows From Operating Activities
Net loss	$ (4,745,743)	$ (3,180,419)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	402,469	140,884
Accretion of interest expense	2,916	6,012
Depreciation and amortization	127,182	89,452
Stock-based compensation	1,355,327	583,673
Loss on extinguishment of note payables, net	16,660	26,029
Warrant modification expense	28,486	10,000
Changes in operating assets and liabilities:
Accounts receivable	77,375	(50,982)
Prepaid expenses and other current assets	15,326	(14,032)
Accounts payable	(377,197)	313,352
Accrued interest, expenses and other current liabilities	361,794	641,873
Deferred revenues		(50,231)
Total Adjustments	2,010,338	1,696,030
Net Cash Used In Operating Activities	(2,735,405)	(1,484,389)
Cash Flows From Investing Activities
Purchases of property and equipment	(151,200)	(151,914)
License maintenance costs		(75,000)
Net Cash Used In Investing Activities	(151,200)	(226,914)
Cash Flows From Financing Activities
Deferred offering costs		(8,050)
Proceeds from notes payable	980,000	515,000
Repayments of notes payable	(118,500)
Advances from an officer	89,045	274,085
Repayments of advances from an officer and a director	(160,575)	(206,085)
Proceeds from exercise of warrants	212,898
Sales of common stock and warrants for cash	2,233,372	1,051,000
Net Cash Provided By Financing Activities	3,236,240	1,625,950
Net Increase (Decrease) In Cash	349,635	(85,353)
Cash - Beginning	166,555	91,798
Cash - Ending	516,190	6,445
Supplemental Disclosures of Cash Flow Information:
Interest	15,000	46,161
Non-cash investing and financing activities:
Warrant modification in connection with extension or exchanges of notes payable		5,900
Shares and warrants issued in connection with issuance or extension of notes payable	129,613	54,415
Shares and warrants issued in exchange for notes payable and accrued interest	231,480	5,116,036
Conversion of notes payable and accrued interest into common stock	215,158	170,065
Shares issued in satisfaction of accrued consulting and director services	27,553	8,481
Beneficial conversion features set up as debt discount	215,446	10,690
Accrued liabilities associated with purchases of property and equipment		109,487
Accrued deferred offering costs		144,117
Shares and warrants issued in connection with settlement agreement		152,000
Indebtness satisfied via legal settlement		$ 5,000

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation BioRestorative Therapies, Inc. has two wholly-owned subsidiaries, Stem Pearls, LLC (“Stem Pearls”) and Stem Cell Cayman Ltd. (“Cayman”), which was formed in the Cayman Islands (collectively, “BRT” or the “Company”). BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com www.stempearls.com The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2016 and for the three and six months ended June 30, 2016 and 2015. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the operating results for the full year ending December 31, 2016 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2015 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 30, 2016. Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split of the Company’s issued and outstanding common stock (the “Reverse Split”) and a reduction in the number of shares of common stock authorized to be issued by the Company from 200,000,000 to 30,000,000. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented.

Going Concern and Management's

Going Concern and Management's Plans	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Going Concern and Management Plans	Note 2 – Going Concern and Management’s Plans As of June 30, 2016, the Company had a working capital deficiency and a stockholders’ deficiency of $5,151,918 and $4,004,873, respectively. During the three and six months ended June 30, 2016, the Company incurred net losses of $2,258,415 and $4,745,743, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate the continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to June 30, 2016, we have received aggregate equity and debt financing of $340,000 and $300,000, respectively, debt and accrued interest of $288,000 and $14,954, respectively, has been repaid and debt and accrued interest of $55,000 and $3,195, respectively, has been converted into common stock. As a result, the Company expects to have the cash required to fund its operations through September 2016. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $157,500 which are past due. The Company is currently in the process of negotiating extensions or discussing conversions to equity with respect to these notes. However, there can be no assurance that the Company will be successful in extending or converting these notes. See Note 8 – Subsequent Events for additional details.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Concentrations and Credit Risk Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three and six months ended June 30, 2015. See Revenue Recognition – Research and Development Agreements below. Revenue Recognition Research and Development Agreements During the three and six months ended June 30, 2016, the Company recognized no revenue related to research and development agreements. During the three and six months ended June 30, 2015, the Company recognized revenue related to research and development agreements of $146,764 and $327,466, respectively. Other During the three and six months ended June 30, 2016, the Company recognized $16,000 and $25,000, respectively, of revenue related to the Company’s sublicense agreement. During the three and six months ended June 30, 2015, the Company has recognized $2,000 and $6,000 respectively, of revenue related to the Company’s sublicense agreement. During the three and six months ended June 30, 2016, the Company recognized revenue related to sales of Stem Pearls skincare products of $155 and $280, respectively. During the three and six months ended June 30, 2015, the Company recognized revenue related to sales of Stem Pearls® skincare products of $0 and $200, respectively. Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: June 30, 2016 2015 Options 2,160,950 789,200 Warrants 2,486,286 728,850 Convertible notes 90,297 65,719 Total potentially dilutive shares 4,737,533 1,583,769 Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements, except as disclosed. Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating ASU 2016-09 and its impact on its consolidated financial statements or disclosures. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”). The amendments in this update clarify the following two aspects to Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. The entity first identifies the promised goods or services in the contract and reduces the cost and complexity. An entity evaluates whether promised goods and services are distinct. Topic 606 includes implementation guidance on determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The Company is currently evaluating ASU 2016-10 and its impact on its consolidated financial statements or disclosures.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: June 30, 2016 December 31, 2015 (unaudited) Credit card payable $ 2,500 $ 3,171 Accrued payroll 1,098,538 1,010,633 Advances from related parties 15,500 87,030 Accrued research and development expenses 512,201 446,175 Accrued general and administrative expenses 571,250 456,182 Deferred rent 42,303 43,604 Total $ 2,242,292 $ 2,046,795 During the six months ended June 30, 2016, the Company received an aggregate of $89,045 in non-interest bearing advances from an officer of the Company and made aggregate repayments of $160,575 to an officer and a director of the Company. During the six months ended June 30, 2015, the Company received an aggregate of $274,085 in non-interest bearing advances from an officer of the Company and a family member of an officer of the Company and made aggregate repayments of $206,085.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2016
Notes Payable [Abstract]
Notes Payable	Note 5 – Notes Payable A summary of the notes payable activity during the six months ended June 30, 2016 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, December 31, 2015 $ 150,000 $ 420,000 [1] $ 900,083 $ (158,285 ) $ 1,311,798 Issuance 500,000 140,000 340,000 - 980,000 Exchanges to equity - (160,000 ) (49,018 ) - (209,018 ) Conversion to equity - (205,000 ) - - (205,000 ) Repayments - - (118,500 ) - (118,500 ) Recognition of debt discount - - - (345,059 ) (345,059 ) Amortization of debt discount - - - 402,469 402,469 Accretion of interest expense - - - 2,916 2,916 Outstanding, June 30, 2016 $ 650,000 $ 195,000 [1] $ 1,072,565 $ (97,959 ) $ 1,819,606 [1] As of June 30, 2016 and December 31, 2015, convertible notes with an aggregate principal balance of $195,000 and $420,000, respectively, were convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $145,000 and $197,500, respectively, of principal into shares of common stock. Related Parties Notes As of June 30, 2016, a lender holding a note payable in the principal amount of $150,000 is a related party as a result of having more than 5% beneficial ownership interest in the Company's common stock. On June 30, 2016, the Company borrowed $500,000 from Tuxis Trust (the “Trust”). A director and principal shareholder of the Company serves as a trustee of the Trust, which was established for the benefit of his immediate family. The promissory note evidencing the loan provides for the payment of the principal amount, together with interest at the rate of 10% per annum, on July 1, 2017. In the event that, prior to maturity, the Company receives net proceeds of $10,000,000 from a single equity or debt financing (as opposed to a series of related or unrelated financings), the Trust has the right to require that the Company prepay the amount due under the note (subject to the consent of the party that provided the particular financing). In consideration of the loan, the Company issued to the Trust a five-year immediately vested warrant for the purchase of 40,000 shares of common stock of the Company at an exercise price of $4.00 per share. The $55,659 relative fair value of the warrant has been recorded as debt discount and will be amortized over the term of the note Convertible Notes Issuances On March 7, 2016, the Company issued a convertible note with a principal amount of $75,000 which bears interest at a rate of 10% per annum payable upon maturity. The convertible note is payable as follows: (i) $25,000 of principal and the respective accrued interest on such principal is payable six months from the issuance date (the “March Note First Maturity Date”), (ii) $25,000 of principal and the respective accrued interest on such principal is payable two weeks following the March Note First Maturity Date, and (iii) $25,000 of principal and the respective accrued interest on such principal is payable one month following the March Note First Maturity Date. Each payment of principal and the respective accrued interest is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) 62% of the fair market value of the Company’s stock or (b) $2.00 per share. Should the Company elect to convert any of the note principal and respective accrued interest, the holder will have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note at the same conversion price. The Company will recognize the beneficial conversion feature of the note as debt discount at the time the contingently adjustable conversion ratio is resolved. Issuances On April 27, 2016, the Company issued a convertible note with a principal amount of $65,000 which bears interest at a rate of 10% per annum payable upon maturity. The convertible note is payable as follows: (i) $25,000 of principal and the respective accrued interest on such principal is payable six months from the issuance date (the “April Note First Maturity Date”) , (ii) $20,000 of principal and the respective accrued interest on such principal is payable two weeks following the April Note First Maturity Date, and (iii) $20,000 of principal and the respective accrued interest on such principal is payable one month following the April Note First Maturity Date. Each payment of principal and the respective accrued interest is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) 62% of the fair market value of the Company’s stock or (b) $2.00 per share. Should the Company elect to convert any of the note principal and respective accrued interest, the holder will have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note at the same conversion price. In connection with the issuance of this convertible note, the Company issued a five-year, immediately vested warrant to purchase 7,500 shares of common stock at an exercise price of $4.00 per share. The Company will recognize the beneficial conversion feature of the note as debt discount at the time the contingently adjustable conversion ratio is resolved. The $12,741 relative fair value of the warrant has been recorded as debt discount and is being amortized over the term of the note Conversions, Exchanges and Other During the six months ended June 30, 2016, the Company elected to convert certain convertible notes with an aggregate principal balance of $205,000 and aggregate accrued interest of $10,158 into an aggregate of 76,674 shares of common stock at conversion prices ranging from $2.30 to $3.00 per share. During the six months ended June 30, 2016, the Company and certain lenders agreed to exchange certain convertible notes with an aggregate principal balance of $160,000, along with accrued and unpaid interest of $5,802, for an aggregate of 78,955 shares of common stock at a price of $2.10 per share. The common stock had an aggregate issuance date value of $177,649 and, as a result, the Company recorded a loss on extinguishment of $11,847. During the six months ended June 30, 2016, the contingently adjustable conversion ratio associated with certain convertible notes was resolved and such notes became convertible during the period. The Company estimated the intrinsic value of the embedded conversion option based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the three and six months ended June 30, 2016, the Company recognized $0 and $215,446, respectively, related to the beneficial conversion feature as debt discount which was immediately amortized. During the three and six months ended June 30, 2015, the Company recognized $0 and $10,690, respectively, of intrinsic value related to the beneficial conversion feature as debt discount which was amortized immediately. Other Notes Issuances On February 18, 2016, the Company issued a one-year note payable with a principal amount of $250,000 which bears interest at a rate of 10% per annum payable upon maturity. In connection with the issuance of this promissory note, the Company issued a five-year, immediately vested warrant to purchase 20,000 shares of common stock at an exercise price of $4.00 per share. The $31,009 relative fair value of the warrant has been recorded as debt discount and is being amortized over the term of the note. On April 27, 2016, the Company issued a one-year note payable with a principal amount of $90,000 which bears interest at a rate of 10% per annum payable upon maturity. In connection with the note issuance, the Company issued a five-year, immediately vested warrant to purchase 10,000 shares of common stock at an exercise price of $4.00 per share. The $16,704 relative fair value of the warrant has been recorded as debt discount and is being amortized over the term of the note Exchanges and Other During the six months ended June 30, 2016, the Company and certain lenders agreed to exchange certain other notes with an aggregate principal balance of $49,018 for an aggregate of 23,925 shares of common stock at prices ranging from $1.25 to $2.45 per share. The common stock had an aggregate issuance date value of $53,831 and, as a result, the Company recorded a loss on extinguishment of $4,813. During the six months ended June 30, 2016, the Company and a lender agreed to multiple extensions of the maturity date of a non-interest bearing note payable in the original principal amount of $244,000 from February 5, 2016 to July 15, 2016. In connection with the extensions, the Company (i) paid the lender an aggregate of $111,000 of which $96,000 was repayment of the principal balance and $15,000 was a fee related to the extension which is reflected within interest expense in the unaudited condensed consolidated statements of operations (ii) the lender received 6,000 shares of common stock with a fair value of $13,500 which was recorded as debt discount and amortized over the term of the extension and (iii) the Company and the lender agreed to exchange principal in the amount of $10,000 into 8,000 shares of common stock (included within the exchanges discussed above). As of June 30, 2016, the note has a remaining principal amount of $138,000. See Note 8 – Subsequent Events for additional details related to repayment of the note. During the six months ended June 30, 2016 (excluding amounts repaid as discussed above), the Company repaid an aggregate principal amount of $22,500 of notes payable.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Operating Lease Rent expense amounted to $33,000 and $66,000 for the three and six months ended June 30, 2016, respectively. During the three and six months ended June 30, 2015, the Company recognized approximately $29,000 and $64,000, respectively, of rent expense. Employment Agreements During the six months ended June 30, 2016, the Company’s Compensation Committee and Board of Directors approved performance-based cash bonuses for the year ended December 31, 2016 for the Company’s officers and certain current employees in the aggregate amount of up to $407,000. The Company is accruing for bonus payments which are probable to be achieved over the service period. Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In the opinion of management, such matters are currently not expected to have a material impact on the Company’s financial statements. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Stockholders' Deficiency

Stockholders' Deficiency	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders’ Deficiency	Note 7 – Stockholders’ Deficiency Common Stock and Warrant Offerings During the six months ended June 30, 2016, the Company issued an aggregate of 558,343 shares of common stock and warrants to purchase an aggregate of 1,402,687 shares of common stock at exercise prices ranging from $4.50 to $5.00 per share to investors for aggregate gross proceeds of $2,233,372. Of the aggregate warrants issued, warrants to purchase 444,444, 400,000 and 558,243 shares of common stock had terms of 0.7, 1.0 and 5 years, respectively. The warrants had an aggregate grant date fair value of $1,395,408. Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0% to 5% for options granted during the six months ended June 30, 2016 and 2015. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Warrant Exercises During the six months ended June 30, 2016, warrants to purchase an aggregate of 60,831 shares of common stock were exercised at a reduced exercise price of $3.50 per share (reduced from exercises prices ranging from $4.00 to $15.00 per share) for aggregate gross proceeds of $212,898. The Company recognized a warrant modification charge of $23,448 during the six months ended June 30, 2016, which represents the incremental value of the modified warrants as compared to the original warrants, both valued as of the respective modification dates. Stock Warrants In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For The Three Months Ended For The Six Months Ended June 30, June 30, 2016 2015 2016 2015 Risk free interest rate 1.01% - 1.41 % 1.32% - 1.71 % 0.44% - 1.47 % 1.22% - 1.71 % Expected term (years) 5.00 5.00 0.67 - 5.00 5.00 Expected volatility 126 % 121% - 122% 124% - 126% 121% - 122% Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three and six months ended June 30, 2016 was approximately $1.02 and $1.76 per share, respectively. The weighted average estimated fair value of the warrants granted during the three and six months ended June 30, 2015 was $3.76 and $3.60 per share, respectively During the six months ended June 30, 2016, the Company reduced the exercise price of previously outstanding warrants to purchase an aggregate of 12,916 shares of common stock from an exercise price of $15.00 per share to a new exercise price of $4.00 per share and recognized $5,038 of incremental expense related to the modification of the warrants which is reflected in warrant modification expense in the unaudited condensed consolidated statements of operations. The Company recorded no stock–based compensation expense during the three and six months ended June 30, 2016 and 2015 related to stock warrants issued as compensation. As of June 30, 2016, there was no unrecognized stock-based compensation expense related to stock warrants. A summary of the warrant activity during the six months ended June 30, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2016 1,066,930 $ 7.56 [1] Issued 1,480,187 4.80 Exercised (60,831 ) 3.50 Forfeited - - Outstanding, June 30, 2016 2,486,286 $ 5.76 [1] 3.5 $ - Exercisable, June 30, 2016 2,451,286 $ 5.76 3.6 $ - [1] Excludes the impact of a warrant to purchase 35,000 shares of common stock that has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the six months ended June 30, 2016. Stock Options In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Three Months Ended For the Six Months Ended June 30, June 30, 2016 2015 2016 2015 Risk free interest rate 1.17 % 1.49 % 1.17% - 1.53 % 1.33% - 1.64 % Expected term (years) 5.50 - 6.00 6.00 5.50 - 6.00 5.00 - 6.00 Expected volatility 126 % 121 % 124% - 126 % 121% - 122 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the options granted during the three and six months ended June 30, 2016 was $3.24 and $3.25 per share, respectively. The weighted average estimated fair value of the options granted during the three and six months ended June 30, 2015 was $6.94 and $7.64 per share, respectively. On June 10, 2016, the Company issued ten-year options to employees, directors and advisors to purchase an aggregate of 827,000 shares of common stock at an exercise price of $3.73 per share, pursuant to the Plan. The shares vest as follows: (i) 192,333 shares vest immediately, (ii) 384,667 shares vest ratably over two years on the issuance date anniversaries and (iii) 250,000 shares vest ratably over three years on the issuance date anniversaries. The options had an aggregate grant date value of $2,682,800. The following table presents information related to stock option expense: Weighted Average For the Three Months Ended For the Six Months Ended Remaining Amortization June 30, June 30, Unrecognized at Period 2016 2015 2016 2015 June 30, 2016 (Years) Consulting $ 439,644 $ 21,427 $ 543,742 $ 118,230 $ 1,238,687 1.9 Research and development 75,156 104,720 182,339 233,152 1,200,154 2.4 General and administrative 442,450 63,859 592,163 133,144 1,484,879 1.9 $ 957,250 $ 190,006 $ 1,318,244 $ 484,526 $ 3,923,720 2.1 A summary of the stock option activity during the six months ended June 30, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2015 1,330,450 $ 10.11 Granted 842,000 3.73 Exercised - - Forfeited (11,500 ) - Outstanding, June 30, 2016 2,160,950 $ 7.61 8.7 $ - Exercisable, June 30, 2016 922,119 $ 10.61 8.0 $ - Compensatory Common Stock Issuances The following table presents information related to compensatory common stock expense: For The Three Months Ended For The Six Months Ended Unrecognized at June 30, June 30, June 30, 2016 2015 2016 2015 2016 Consulting $ (13,541 ) $ 22,500 $ 37,083 $ 90,300 $ - Research and development - - - 8,847 - $ (13,541 ) $ 22,500 $ 37,083 $ 99,147 $ - Return of Shares to Treasury On June 27, 2016, the Company and a consultant agreed that, due to the amount and nature of the services performed, the consultant would return 7,500 shares of common stock to the Company with a fair value of $16,875. Accordingly the Company recorded the treasury shares at cost with a stock-based compensation credit which is reflected within consulting expense in the unaudited condensed consolidated statements of operations.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events Notes Payable Subsequent to June 30, 2016, the Company issued six-month notes payable in the aggregate principal amount of $342,000 for cash consideration of $300,000. The notes bear interest at rates ranging from 0% to 10% per annum, payable at maturity. In connection with the issuances, the Company issued a note holder an immediately vested five-year warrant to purchase 8,000 shares of common stock at an exercise price of $4.00 per share. Subsequent to June 30, 2016, the Company elected to convert certain convertible notes with an aggregate principal balance of $55,000 and aggregate accrued interest of $3,195 into an aggregate of 25,902 shares of common stock at a conversion price of $2.25 per share. Subsequent to June 30, 2016 the Company repaid aggregate principal and interest amounts of $288,000 and $14,954, respectively. 2010 Equity Participation Plan On August 15, 2016, the Compensation Committee of the Board increased the number of shares authorized to be issued pursuant to the Company’s 2010 Equity Participation Plan from 2,250,000 to 4,250,000, subject to stockholder approval. Common Stock and Warrant Offerings Subsequent to June 30, 2016, the Company issued an aggregate of 89,167 shares of common stock and immediately vested five-year warrants to purchase an aggregate of 89,617 shares of common stock at exercise prices ranging from $4,00 to $5.00 per share to investors for aggregate gross proceeds of $340,000. In connection with the issuances, the Company reduced the exercise price of an aggregate of 31,250 warrants with original exercise prices ranging from $6.00 per share to $10,00 per share to an exercise price of $4,00 per share. Stock-Based Compensation Subsequent to June 30, 2016, the Company issued 24,000 shares of common stock to a consultant pursuant to a consulting agreement for services. Short Term Advances Subsequent to June 30, 2016, the Company received an aggregate of $30,015 in non-interest bearing advances from an officer of the Company and made aggregate repayments of $45,515 in non-interest bearing advances to an officer of the Company.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations and Credit Risk	Concentrations and Credit Risk Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three and six months ended June 30, 2015. See Revenue Recognition – Research and Development Agreements below.
Revenue Recognition	Revenue Recognition Research and Development Agreements During the three and six months ended June 30, 2016, the Company recognized no revenue related to research and development agreements. During the three and six months ended June 30, 2015, the Company recognized revenue related to research and development agreements of $146,764 and $327,466, respectively. Other During the three and six months ended June 30, 2016, the Company recognized $16,000 and $25,000, respectively, of revenue related to the Company’s sublicense agreement. During the three and six months ended June 30, 2015, the Company has recognized $2,000 and $6,000 respectively, of revenue related to the Company’s sublicense agreement. During the three and six months ended June 30, 2016, the Company recognized revenue related to sales of Stem Pearls skincare products of $155 and $280, respectively. During the three and six months ended June 30, 2015, the Company recognized revenue related to sales of Stem Pearls® skincare products of $0 and $200, respectively.
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: June 30, 2016 2015 Options 2,160,950 789,200 Warrants 2,486,286 728,850 Convertible notes 90,297 65,719 Total potentially dilutive shares 4,737,533 1,583,769
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements, except as disclosed.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating ASU 2016-09 and its impact on its consolidated financial statements or disclosures. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”). The amendments in this update clarify the following two aspects to Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. The entity first identifies the promised goods or services in the contract and reduces the cost and complexity. An entity evaluates whether promised goods and services are distinct. Topic 606 includes implementation guidance on determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The Company is currently evaluating ASU 2016-10 and its impact on its consolidated financial statements or disclosures.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Schedule of Weighted Average Dilutive Common Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: June 30, 2016 2015 Options 2,160,950 789,200 Warrants 2,486,286 728,850 Convertible notes 90,297 65,719 Total potentially dilutive shares 4,737,533 1,583,769

Accrued Expenses and Other Cu17

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: June 30, 2016 December 31, 2015 (unaudited) Credit card payable $ 2,500 $ 3,171 Accrued payroll 1,098,538 1,010,633 Advances from related parties 15,500 87,030 Accrued research and development expenses 512,201 446,175 Accrued general and administrative expenses 571,250 456,182 Deferred rent 42,303 43,604 Total $ 2,242,292 $ 2,046,795

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Payable [Abstract]
Schedule of Notes Payable Activity	A summary of the notes payable activity during the six months ended June 30, 2016 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, December 31, 2015 $ 150,000 $ 420,000 [1] $ 900,083 $ (158,285 ) $ 1,311,798 Issuance 500,000 140,000 340,000 - 980,000 Exchanges to equity - (160,000 ) (49,018 ) - (209,018 ) Conversion to equity - (205,000 ) - - (205,000 ) Repayments - - (118,500 ) - (118,500 ) Recognition of debt discount - - - (345,059 ) (345,059 ) Amortization of debt discount - - - 402,469 402,469 Accretion of interest expense - - - 2,916 2,916 Outstanding, June 30, 2016 $ 650,000 $ 195,000 [1] $ 1,072,565 $ (97,959 ) $ 1,819,606 [1] As of June 30, 2016 and December 31, 2015, convertible notes with an aggregate principal balance of $195,000 and $420,000, respectively, were convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $145,000 and $197,500, respectively, of principal into shares of common stock.

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Schedule of Share based Payment Award Stock Warrants Valuation Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For The Three Months Ended For The Six Months Ended June 30, June 30, 2016 2015 2016 2015 Risk free interest rate 1.01% - 1.41 % 1.32% - 1.71 % 0.44% - 1.47 % 1.22% - 1.71 % Expected term (years) 5.00 5.00 0.67 - 5.00 5.00 Expected volatility 126 % 121% - 122% 124% - 126% 121% - 122% Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Schedule of Warrant Activity	A summary of the warrant activity during the six months ended June 30, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2016 1,066,930 $ 7.56 [1] Issued 1,480,187 4.80 Exercised (60,831 ) 3.50 Forfeited - - Outstanding, June 30, 2016 2,486,286 $ 5.76 [1] 3.5 $ - Exercisable, June 30, 2016 2,451,286 $ 5.76 3.6 $ - [1] Excludes the impact of a warrant to purchase 35,000 shares of common stock that has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the three months ended March 31, 2016.
Schedule of Share based Payment Award Stock Options Valuation Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Three Months Ended For the Six Months Ended June 30, June 30, 2016 2015 2016 2015 Risk free interest rate 1.17 % 1.49 % 1.17% - 1.53 % 1.33% - 1.64 % Expected term (years) 5.50 - 6.00 6.00 5.50 - 6.00 5.00 - 6.00 Expected volatility 126 % 121 % 124% - 126 % 121% - 122 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Schedule of Stock Option Expense	The following table presents information related to stock option expense: Weighted Average For the Three Months Ended For the Six Months Ended Remaining Amortization June 30, June 30, Unrecognized at Period 2016 2015 2016 2015 June 30, 2016 (Years) Consulting $ 439,644 $ 21,427 $ 543,742 $ 118,230 $ 1,238,687 1.9 Research and development 75,156 104,720 182,339 233,152 1,200,154 2.4 General and administrative 442,450 63,859 592,163 133,144 1,484,879 1.9 $ 957,250 $ 190,006 $ 1,318,244 $ 484,526 $ 3,923,720 2.1
Schedule of Stock Option Activity	A summary of the stock option activity during the six months ended June 30, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2015 1,330,450 $ 10.11 Granted 842,000 3.73 Exercised - - Forfeited (11,500 ) - Outstanding, June 30, 2016 2,160,950 $ 7.61 8.7 $ - Exercisable, June 30, 2016 922,119 $ 10.61 8.0 $ -
Schedule of Common Stock Expense	The following table presents information related to compensatory common stock expense: For The Three Months Ended For The Six Months Ended Unrecognized at June 30, June 30, June 30, 2016 2015 2016 2015 2016 Consulting $ (13,541 ) $ 22,500 $ 37,083 $ 90,300 $ - Research and development - - - 8,847 - $ (13,541 ) $ 22,500 $ 37,083 $ 99,147 $ -

Business Organization, Nature20

Business Organization, Nature of Operations and Basis of Presentation (Details Narrative) - shares	Jul. 07, 2015	Jun. 30, 2016	Dec. 31, 2015
Reverse stock split	1-for-20 reverse split
Common stock, shares Authorized		30,000,000	30,000,000
Minimum [Member]
Common stock, shares Authorized		200,000,000
Maximum [Member]
Common stock, shares Authorized		30,000,000

Going Concern and Management'21

Going Concern and Management's Plans (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Apr. 27, 2016	Mar. 07, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Working capital deficiency	$ 5,151,918		$ 5,151,918
Stockholder's deficiency	4,004,873		4,004,873				$ 3,908,463
Net loss	2,258,415	$ 1,420,298	4,745,743	$ 3,180,419
Received aggregate equity			340,000
Proceeds from debt financing			300,000
Amount of debt			288,000
Financing accrued interest			14,954
Repayments of debt			55,000
Accrued interest			3,195
Notes payable aggregate principal past due	$ 157,500		$ 157,500		$ 65,000	$ 75,000

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Summary Of Significant Accounting Policies [Line Items]
Revenues	$ 16,155	$ 148,764	$ 25,280	$ 333,666
Stem Pearls Skincare Products [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue recognized	155	0	280	200
Research and Development Agreements [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenues	0	146,764	0	327,466
Sublicense Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue recognized	$ 16,000	$ 2,000	$ 25,000	$ 6,000

Summary of Significant Accoun23

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	4,737,533	1,583,769
Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	2,160,950	789,200
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	2,486,286	728,850
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	90,297	65,719

Accrued Expenses and Other Cu24

Accrued Expenses and Other Current Liabilities (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer	$ 89,045	$ 274,085
Repayment of advances from officer	160,575	206,085
Non-Interest Bearing Advance [Member]
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer	89,045	274,085
Repayment of advances from officer	$ 160,575	$ 206,085

Accrued Expenses and Other Cu25

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Disclosure Accrued Expenses and Other Current Liabilities [Abstract]
Credit card payable	$ 2,500	$ 3,171
Accrued payroll	1,098,538	1,010,633
Advances from related parties	15,500	87,030
Accrued research and development expenses	512,201	446,175
Accrued general and administrative expenses	571,250	456,182
Deferred rent	42,303	43,604
Total	$ 2,242,294	$ 2,046,795

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jun. 30, 2016	Apr. 27, 2016	Mar. 07, 2016	Feb. 18, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Debt instrument, face amount	$ 157,500	$ 65,000	$ 75,000		$ 157,500		$ 157,500
Borrowed from related party							89,045	$ 274,085
Debt instrument interest rate interest		10.00%	10.00%
Common stock an exercise price per share		$ 2	$ 2
Debt instrument conversion period description		(a) 62% of the fair market value of the Company’s stock or (b) $2.00 per share.	(a) 62% of the fair market value of the Companys stock or (b) $2.00 per share. Should the Company elect to convert any of the note principal and respective accrued interest, the holder will have the right to accelerate the conversion of the remaining outstanding principal and accrued interest of the note.
Loss on extinguishment of note payables, net					4,813	$ 26,029	16,660	26,029
Debt Instrument, Convertible, Beneficial Conversion Feature					$ 0	$ 0	215,446	$ 10,690
Aggregate issuance date value							2,233,372
Agreed to exchange principal amount							215,158
Repayments of debt							55,000
Other Notes [Member]
Debt Instrument [Line Items]
Debt conversion, original debt, amount							$ 160,000
Debt instrument, convertible, conversion price	$ 2.10				$ 2.10		$ 2.10
Conversion of stock, shares issued							78,955
Accrued interest converted into stock	$ 5,802				$ 5,802		$ 5,802
Warrants and rights outstanding	177,649				177,649		177,649
Loss on extinguishment of note payables, net							11,847
OtherNotes Issuances [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 90,000		$ 250,000
Debt instrument interest rate interest		10.00%		10.00%
Warrant issued term		5 years		5 years
Share based arrangements vested warrant to purchase		10,000		20,000
Common stock an exercise price per share		$ 4		$ 4
Fair value of class of warrant		$ 16,704		$ 31,009
Exchanges And Other [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 138,000				$ 138,000		138,000
Debt instrument, periodic payment, principal							15,000
Loss on extinguishment of note payables, net							$ 4,813
Aggregate number of shares of common stock							23,925
Aggregate issuance date value							$ 53,831
Repayments of debt							22,500
Exchanges And Other [Member] | February 5, 2016 to July 15, 2016 [Member]
Debt Instrument [Line Items]
Debt instrument, periodic payment, principal							111,000
Debt conversion, original debt, amount							$ 244,000
Exchanges And Other [Member] | Minimum [Member]
Debt Instrument [Line Items]
Issued shares per share price	$ 1.25				$ 1.25		$ 1.25
Exchanges And Other [Member] | Maximum [Member]
Debt Instrument [Line Items]
Issued shares per share price	$ 2.45				$ 2.45		$ 2.45
Warrant [Member]
Debt Instrument [Line Items]
Share based arrangements vested warrant to purchase		7,500
Common stock an exercise price per share		$ 4
Fair value of class of warrant		$ 12,741
Tuxis Trust [Member]
Debt Instrument [Line Items]
Borrowed from related party	$ 500,000
Debt instrument interest rate interest	10.00%				10.00%		10.00%
Proceeds from single equity or debt financing	$ 100,000,000
Warrant issued term	5 years
Share based arrangements vested warrant to purchase	40,000
Common stock an exercise price per share	$ 4				$ 4		$ 4
Fair value of class of warrant	$ 55,659				$ 55,659		$ 55,659
Lenders [Member] | Convertible Notes [Member]
Debt Instrument [Line Items]
Debt conversion, original debt, amount							205,000
Original debt accrued interest converted into stock	$ 10,158				$ 10,158		$ 10,158
Debt conversion original debt shares issued							76,674
Lenders [Member] | Convertible Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 2.30				$ 2.30		$ 2.30
Lenders [Member] | Convertible Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 3				$ 3		$ 3
Lenders [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 49,018				$ 49,018		$ 49,018
Lenders [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Aggregate number of shares of common stock							6,000
Aggregate issuance date value							$ 13,500
Agreed to exchange principal amount							$ 10,000
Agreed to exchange principal amount, shares							8,000
Related Parties Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 150,000				$ 150,000		$ 150,000
Beneficial ownership percentage	5.00%				5.00%		5.00%
First Maturity Date [Member]
Debt Instrument [Line Items]
Debt instrument, periodic payment, principal		25,000	$ 25,000
Second Maturity Date [Member]
Debt Instrument [Line Items]
Debt instrument, periodic payment, principal		20,000	25,000
Third Maturity Date [Member]
Debt Instrument [Line Items]
Debt instrument, periodic payment, principal		$ 20,000	$ 25,000
Principal Balance [Member] | Exchanges And Other [Member] | February 5, 2016 to July 15, 2016 [Member]
Debt Instrument [Line Items]
Debt instrument, periodic payment, principal							$ 96,000
Fee Related To The Extension [Member] | Exchanges And Other [Member] | February 5, 2016 to July 15, 2016 [Member]
Debt Instrument [Line Items]
Debt instrument, periodic payment, principal							$ 15,000

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable Activity (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Outstanding				$ 1,311,798
Issuance				980,000
Exchanges to equity				(209,018)
Conversion to equity				(205,000)
Repayments				(118,500)
Recognition of debt discount				(345,059)
Amortization of debt discount		$ 65,448	$ 71,369	402,469	140,884
Accretion of interest expense				2,916	$ 6,012
Outstanding		1,819,606		1,819,606
Convertible Notes [Member]
Debt Instrument [Line Items]
Outstanding	[1]			420,000
Issuance				140,000
Exchanges to equity				(160,000)
Conversion to equity				(205,000)
Repayments
Recognition of debt discount
Amortization of debt discount
Accretion of interest expense
Outstanding	[2]	195,000		195,000
Other Notes [Member]
Debt Instrument [Line Items]
Outstanding				900,083
Issuance				340,000
Exchanges to equity				(49,018)
Conversion to equity
Repayments				(118,500)
Recognition of debt discount
Amortization of debt discount
Accretion of interest expense
Outstanding		1,072,565		1,072,565
Debt Discount [Member]
Debt Instrument [Line Items]
Outstanding				(158,285)
Issuance
Exchanges to equity
Conversion to equity
Repayments
Recognition of debt discount				(345,059)
Amortization of debt discount				402,469
Accretion of interest expense				2,916
Outstanding		(97,959)		(97,959)
Related Party Notes [Member]
Debt Instrument [Line Items]
Outstanding				150,000
Issuance				500,000
Exchanges to equity
Conversion to equity
Repayments
Recognition of debt discount
Amortization of debt discount
Accretion of interest expense
Outstanding		$ 650,000		$ 650,000
[1]	As of June 30, 2016 and December 31, 2015, convertible notes with an aggregate principal balance of $209,018 and $420,000, respectively, become convertible into shares of common stock at the election of the Company near maturity. Of such aggregate principal balance the holder has the right to accelerate the conversion of up to $________ and $197,500, respectively, of principal into shares of common stock.
[2]	As of March 31, 2016 and December 31, 2015, convertible notes with an aggregate principal balance of $185,000 and $420,000, respectively, become convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercises that conversion right on a designated portion of such principal balance, the holder has the right to accelerate the conversion of up to $132,500 and $197,500, respectively, of principal into shares of common stock.

Notes Payable - Schedule of N28

Notes Payable - Schedule of Notes Payable Activity (Details) (Parenthetical) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Notes Payable [Abstract]
Aggregate principal amount	$ 195,000		$ 420,000
Conversion of Stock, Description	In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $145,000 and $197,500, respectively, of principal into shares of common stock.
Rights to conversion of principal into shares of common stock	$ 145,000	$ 197,500

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Rent expense	$ 33,000	$ 29,000	$ 66,000	$ 640,000
Chief Executive Officer Employment Agreements [Member]
Employees aggregate	$ 407,000		$ 407,000

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Proceeds from warrant exercise			$ 212,898
Warrant modification charge			$ 28,486
Purchase of shares of common stock			842,000
Consultant [Member]
Purchase of treasury shares			7,500
Purchase of treasury shares fair value			$ 16,875
Stock Options [Member]
Weighted average estimated fair value of the warrants granted	$ 3.24	$ 6.94	$ 3.25	$ 7.64
Purchase of shares of common stock			827,000
Number of shares vested			192,333
Aggregate grant date value			$ 2,682,800
Stock Offering One [Member]
Warrants to purchase shares of common stock	444,444		444,444
Common stock term			8 months 12 days
Stock Offering Two [Member]
Warrants to purchase shares of common stock	400,000		400,000
Common stock term			1 year
Stock Offering Three [Member]
Warrants to purchase shares of common stock	558,243		558,243
Common stock term			5 years
Common Stock And Warrant Offerings [Member]
Number of shares issued for common stock			558,343
Warrants to purchase shares of common stock	1,402,687		1,402,687
Fair value of warrant			$ 1,395,408
Proceeds from warrant exercise			$ 2,233,372
Common Stock And Warrant Offerings [Member] | Minimum [Member]
Number of common stock at exercise price	$ 4.50		$ 4.50
Common Stock And Warrant Offerings [Member] | Maximum [Member]
Number of common stock at exercise price	$ 5		$ 5
Warrant And Option Valuation [Member] | Minimum [Member]
Estimated Forfeitures Related To Option Grants at an Annual Rate			0.00%
Warrant And Option Valuation [Member] | Maximum [Member]
Estimated Forfeitures Related To Option Grants at an Annual Rate			5.00%
Warrant Exercises [Member]
Warrants to purchase shares of common stock	60,831		60,831
Number of common stock at exercise price	$ 3.50		$ 3.50
Proceeds from warrant exercise			$ 212,898
Warrant modification charge			$ 23,448
Warrant Exercises [Member] | Minimum [Member]
Number of common stock at exercise price	4		$ 4
Warrant Exercises [Member] | Maximum [Member]
Number of common stock at exercise price	$ 15		$ 15
Stock Warrants [Member]
Warrants to purchase shares of common stock	12,916		12,916
Number of common stock at exercise price	$ 15		$ 15
New exercise price per share	4		4
Weighted average estimated fair value of the warrants granted	$ 1.02	$ 3.76	$ 1.76	$ 3.60
Incremental expense related to modification	$ 5,038		$ 5,038
Stock Options [Member]
Option exercise price	$ 3.73		$ 3.73
Stock Options [Member] | Over Two Years [Member]
Number of shares vested			384,667
Stock Options [Member] | Over Three Years [Member]
Number of shares vested			250,000

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Share based Payment Award Warrants Valuation Assumptions (Details) - Warrant [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years	5 years		5 years
Expected volatility	126.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.01%	1.71%	0.44%	1.71%
Expected term (years)			8 months 1 day
Expected volatility		122.00%	124.00%	122.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.41%	1.32%	1.47%	1.22%
Expected term (years)			5 years
Expected volatility		121.00%	126.00%	121.00%

Stockholders' Deficiency - Summ

Stockholders' Deficiency - Summary of Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 10.11
Weighted Average Exercise Price Outstanding, Exercised
Weighted Average Exercise Price Outstanding, Forfeited
Weighted Average Exercise Price Outstanding, Ending Balance	7.61
Weighted Average Exercise Price Exercisable, Balance	$ 10.61
Weighted Average Remaining Life In Years Outstanding	8 years 8 months 12 days
Weighted Average Remaining Life In Years Exercisable	8 years
Aggregate Intrinsic Value, Outstanding | $
Aggregate Intrinsic Value, Exercisable | $
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Beginning Balance | shares	1,066,930
Number of Warrants Outstanding, Investor grants | shares	1,480,187
Number of Warrants Outstanding, Exercised | shares	(60,831)
Number of Warrants Outstanding, Forfeited | shares
Number of Warrants Outstanding, Ending Balance | shares	2,486,286
Number of Warrants Exercisable, Balance | shares	2,451,286
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 7.56	[1]
Weighted Average Exercise Price Outstanding, Investor grants	4.80
Weighted Average Exercise Price Outstanding, Exercised	3.50
Weighted Average Exercise Price Outstanding, Forfeited
Weighted Average Exercise Price Outstanding, Ending Balance	5.76
Weighted Average Exercise Price Exercisable, Balance	$ 5.76
Weighted Average Remaining Life In Years Outstanding	3 years 6 months
Weighted Average Remaining Life In Years Exercisable	3 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding | $
Aggregate Intrinsic Value, Exercisable | $
[1]	Excludes the impact of a warrant to purchase 35,000 shares of common stock that has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the three months ended March 31, 2016.

Stockholders' Deficiency - Su33

Stockholders' Deficiency - Summary of Warrant Activity (Details) (Parenthetical) - Warrant [Member]	Jun. 30, 2016$ / sharesshares
Warrants to purchase shares of common stock | shares	35,000
Exercise price per share | $ / shares	$ 30

Stockholders' Deficiency - Sc34

Stockholders' Deficiency - Schedule of Share based Payment Award Stock Option Granted Assumptions (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Option [Member]
Risk free interest rate	1.17%	1.49%
Expected term (years)		6 years
Expected volatility	126.00%	121.00%
Expected dividends	0.00%	0.00%
Stock Options [Member]
Expected dividends			0.00%	0.00%
Minimum [Member] | Option [Member]
Risk free interest rate			1.17%	1.33%
Expected term (years)	5 years 6 months		5 years 6 months	5 years
Expected volatility			124.00%	121.00%
Maximum [Member] | Option [Member]
Risk free interest rate			1.53%	1.64%
Expected term (years)	6 years		6 years	6 years
Expected volatility			126.00%	122.00%

Stockholders' Deficiency - Info

Stockholders' Deficiency - Information Related to Stock Option Expense (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense			$ 1,318,244	$ 484,526
Unrecognized expense	$ 3,923,720		$ 3,923,720
Weighted Average Remaining Amortization Period			2 years 1 month 6 days
Option [Member] | Consulting Expense [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	439,644	$ 21,427	$ 543,742	118,230
Unrecognized expense	1,238,687		$ 1,238,687
Weighted Average Remaining Amortization Period			1 year 10 months 24 days
Option [Member] | Research and Development Expense [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	75,156	104,720	$ 182,339	233,152
Unrecognized expense	1,200,154		$ 1,200,154
Weighted Average Remaining Amortization Period			2 years 4 months 24 days
Option [Member] | General and Administrative Expense [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	442,450	63,859	$ 592,163	$ 133,144
Unrecognized expense	1,484,879		$ 1,484,879
Weighted Average Remaining Amortization Period			1 year 10 months 24 days
Stock Options [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 957,250	$ 190,006

Stockholders' Deficiency - Su36

Stockholders' Deficiency - Summary of Stock Option (Details)	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares
Stockholders Deficiency - Summary Of Stock Option Details
Number of Options, Outstanding, beginning | shares	1,330,450
Number of Options, Granted | shares	842,000
Number of Options, Exercised | shares
Number of Options, Forfeited | shares	(11,500)
Number of Options, Outstanding at ending | shares	2,160,950
Number of Options, Exercisable | shares	922,119
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 10.11
Weighted Average Exercise Price, Granted | $ / shares	3.73
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	7.61
Weighted Average Exercise Price Exercisable, Balance | $ / shares	$ 10.61
Weighted Average Remaining Life In Years Outstanding	8 years 8 months 12 days
Weighted Average Remaining Life In Years Exercisable	8 years
Aggregate Intrinsic Value, Outstanding | $
Aggregate Intrinsic Value, Exercisable | $

Stockholders' Deficiency - In37

Stockholders' Deficiency - Information Related to Common Stock Award Expense (Detail) - Common Stock Award [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ (13,541)	$ 22,500	$ 37,083	$ 99,147
Unrecognized expense	0		0
Consulting Expense [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	(13,541)	22,500	37,083	90,300
Unrecognized expense	0		0
Research and Development Expense [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense			0	$ 8,847
Unrecognized expense	$ 0		$ 0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Aug. 15, 2016	Apr. 27, 2016	Mar. 07, 2016	Dec. 31, 2015	Dec. 31, 2014
Debt instrument, face amount	$ 157,500			$ 65,000	$ 75,000
Cash consideration	516,190	$ 6,445				$ 166,555	$ 91,798
Note bear interest rate				10.00%	10.00%
Aggregate principal and interest amount	$ 118,500
Subsequent Event [Member] | Warrant Offerings [Member]
Warrant term	5 years
Warrant to purchase common stock issued in period	31,250
Class of warrant or right, exercise price of warrants or rights	$ 4
Number of shares issued for common stock	89,167
Subsequent Event [Member] | Warrant Offerings [Member] | Investors [Member]
Warrant to purchase common stock issued in period	89,617
Proceeds from issuance of warrants	$ 340,000
Subsequent Event [Member] | Stock-Based Compensation [Member]
Number of common stock issued consulting for services	24,000
Subsequent Event [Member] | Minimum [Member] | Warrant Offerings [Member]
Class of warrant or right, exercise price of warrants or rights	$ 6
Subsequent Event [Member] | Minimum [Member] | Warrant Offerings [Member] | Investors [Member]
Class of warrant or right, exercise price of warrants or rights	4
Subsequent Event [Member] | Minimum [Member] | 2010 Equity Participation Plan [Member]
Number of shares authorized to issued			2,250,000
Subsequent Event [Member] | Maximum [Member] | Warrant Offerings [Member]
Class of warrant or right, exercise price of warrants or rights	10
Subsequent Event [Member] | Maximum [Member] | Warrant Offerings [Member] | Investors [Member]
Class of warrant or right, exercise price of warrants or rights	$ 6
Subsequent Event [Member] | Maximum [Member] | 2010 Equity Participation Plan [Member]
Number of shares authorized to issued			4,250,000
Subsequent Event [Member] | Notes Payable [Member]
Debt instrument, face amount	$ 342,000
Cash consideration	$ 300,000
Warrant term	5 years
Warrant to purchase common stock issued in period	8,000
Class of warrant or right, exercise price of warrants or rights	$ 4
Subsequent Event [Member] | Notes Payable [Member] | Minimum [Member]
Note bear interest rate	0.00%
Subsequent Event [Member] | Notes Payable [Member] | Maximum [Member]
Note bear interest rate	10.00%
Subsequent Event [Member] | Convertible Notes Payable [Member]
Debt instrument, face amount	$ 55,000
Accrued interest	$ 3,195
Aggregate shares of common stock conversion	25,902
Conversion price per share	$ 2.25
Aggregate principal and interest amount	$ 288,000
Interest amounts	14,954
Subsequent Event [Member] | Short Term Advances [Member] | Officer [Member]
Aggregate of non-interest bearing advances	30,015
Aggregate repayments non-interest bearing advance	$ 45,515